KR970005912B1 - Amino acids derivatives - Google Patents

Amino acids derivatives Download PDF

Info

Publication number
KR970005912B1
KR970005912B1 KR90020078A KR900020078A KR970005912B1 KR 970005912 B1 KR970005912 B1 KR 970005912B1 KR 90020078 A KR90020078 A KR 90020078A KR 900020078 A KR900020078 A KR 900020078A KR 970005912 B1 KR970005912 B1 KR 970005912B1
Authority
KR
South Korea
Prior art keywords
amino acids
acids derivatives
quinolylcarbonyl
prophylaxis
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR90020078A
Other languages
English (en)
Korean (ko)
Other versions
KR910011894A (ko
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of KR910011894A publication Critical patent/KR910011894A/ko
Application granted granted Critical
Publication of KR970005912B1 publication Critical patent/KR970005912B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Measurement Of Force In General (AREA)
  • Confectionery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR90020078A 1989-12-11 1990-12-07 Amino acids derivatives Expired - Lifetime KR970005912B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
GB8927913.7 1989-12-11
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (2)

Publication Number Publication Date
KR910011894A KR910011894A (ko) 1991-08-07
KR970005912B1 true KR970005912B1 (en) 1997-04-22

Family

ID=26296345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR90020078A Expired - Lifetime KR970005912B1 (en) 1989-12-11 1990-12-07 Amino acids derivatives

Country Status (48)

Country Link
US (1) US5196438A (enExample)
EP (1) EP0432695B1 (enExample)
JP (1) JP2807093B2 (enExample)
KR (1) KR970005912B1 (enExample)
CN (2) CN1034805C (enExample)
AT (1) ATE122661T1 (enExample)
AU (1) AU634319B2 (enExample)
BG (1) BG51452A3 (enExample)
BR (1) BR9006264A (enExample)
CA (1) CA2030433C (enExample)
CU (1) CU22305A3 (enExample)
CZ (1) CZ280558B6 (enExample)
DE (2) DE19675051I2 (enExample)
DK (1) DK0432695T3 (enExample)
DZ (1) DZ1467A1 (enExample)
EG (1) EG19722A (enExample)
ES (1) ES2072959T3 (enExample)
FI (2) FI100883B (enExample)
GB (2) GB8927913D0 (enExample)
GR (1) GR3017114T3 (enExample)
HK (1) HK129093A (enExample)
HR (1) HRP930341B1 (enExample)
HU (2) HU207298B (enExample)
ID (1) ID1018B (enExample)
IE (1) IE67523B1 (enExample)
IL (1) IL96550A (enExample)
IN (1) IN172553B (enExample)
IS (1) IS1803B (enExample)
LT (1) LT3682B (enExample)
LU (1) LU90014I2 (enExample)
LV (1) LV5738B4 (enExample)
MA (1) MA22014A1 (enExample)
MC (1) MC2195A1 (enExample)
MT (1) MTP1075B (enExample)
MW (1) MW8890A1 (enExample)
MX (1) MX173630B (enExample)
NL (1) NL970013I2 (enExample)
NO (1) NO176566C (enExample)
OA (1) OA09334A (enExample)
PL (1) PL165225B1 (enExample)
PT (1) PT96145B (enExample)
RO (1) RO107942B1 (enExample)
RU (1) RU2071470C1 (enExample)
SG (1) SG120493G (enExample)
SI (1) SI9012315B (enExample)
SK (1) SK280249B6 (enExample)
ZA (1) ZA909743B (enExample)
ZW (1) ZW17490A1 (enExample)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
CA2195027C (en) * 1991-11-08 2000-01-11 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
CA2130754C (en) 1992-03-11 2005-02-08 Damian W. Grobelny Amine derivatives of oxo- and hydroxy-substituted hydrocarbons
ATE116640T1 (de) * 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
EP0957093A3 (en) * 1992-05-21 2000-04-12 Monsanto Company Retrovial protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
ES2177868T3 (es) 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
AU6161794A (en) * 1993-01-17 1994-08-15 Schering Corporation Peptides having anti-hiv activity
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ES2098080T3 (es) * 1993-07-15 1997-04-16 Hoffmann La Roche Procedimiento para la obtencion de un derivado de n-tert-butilisoquinolin-3-carboxamida y compuestos intermedios de este procedimiento.
CA2182090A1 (en) * 1994-02-02 1995-08-10 William Joseph Hornback Hiv protease inhibitors and intermediates
DE69512220T2 (de) * 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
SK282121B6 (sk) * 1995-06-06 2001-11-06 F. Hoffmann-La Roche Ag Farmaceutický prostriedok obsahujúci terapeuticky účinné množstvo inhibítora proteinázy
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0861085B1 (en) 1995-11-13 2005-07-20 Vitaleech Bioscience N.V. Anti-viral isolates obtained from leeches
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
EP0847994B1 (de) 1996-12-11 2003-04-09 F. Hoffmann-La Roche Ag Verfahren zur Herstellung gemischter Anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
PT1086076E (pt) * 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
BR9914785A (pt) * 1998-10-21 2001-07-03 Fujisawa Pharmaceutical Co Formavìtrea de 8-[3-[n-[(e)-3-(6-acetamidopiridin-3-il) acriloilglicil]-n-metilamino]-2,6-diclorobenziloxi)-2- metilquinolina, processo para sua preparação, composição farmacêutica compreendendo a mesma, agente de prevenção, seu métodos e uso
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
AU778198B2 (en) * 1999-06-04 2004-11-25 Abbvie Inc. Improved pharmaceutical formulations
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
JP2003504383A (ja) * 1999-07-20 2003-02-04 メルク エンド カムパニー インコーポレーテッド アルファ−ヒドロキシ−ガンマ−[[(炭素環式−又はヘテロ環式−置換)アミノ]カルボニル]アルカンアミド誘導体及びこれらの使用
JP2003514910A (ja) 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Hivプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−2−(フルオロアルキルアミノカルボニル)−1−ピペラジンペンタンアミド類
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
SI1248600T1 (sl) 2000-01-19 2008-08-31 Abbott Lab Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
EP1463807A4 (en) 2001-12-19 2006-04-12 Bristol Myers Squibb Co FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1515944A1 (en) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
KR20070087194A (ko) * 2003-07-11 2007-08-27 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
CN103356622A (zh) * 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
EP2203420A1 (en) * 2007-09-25 2010-07-07 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CL2009002208A1 (es) * 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
CL2009002207A1 (es) * 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivプロテアーゼ阻害剤
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
EP3212196A4 (en) 2014-10-29 2018-07-11 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Also Published As

Publication number Publication date
FI905983L (fi) 1991-06-12
SI9012315A (en) 1997-10-31
FI973895A0 (fi) 1997-10-06
CN1066329C (zh) 2001-05-30
DE19675051I2 (de) 2001-04-12
ZW17490A1 (en) 1992-06-17
PL165225B1 (pl) 1994-11-30
GR3017114T3 (en) 1995-11-30
ZA909743B (en) 1991-08-28
DE69019481T2 (de) 1995-11-09
PT96145B (pt) 1998-04-30
NO176566B (no) 1995-01-16
NL970013I2 (nl) 1997-09-01
EP0432695A2 (en) 1991-06-19
GB2239016B (en) 1993-08-04
AU6787690A (en) 1991-06-13
SG120493G (en) 1994-01-21
CU22305A3 (es) 1995-01-31
IS1803B (is) 2002-02-26
NO176566C (no) 1995-04-26
US5196438A (en) 1993-03-23
MX23619A (es) 1993-10-01
BR9006264A (pt) 1991-09-24
SK576590A3 (en) 1999-10-08
MC2195A1 (fr) 1992-10-05
IS3651A7 (is) 1991-06-12
CZ576590A3 (en) 1995-11-15
NL970013I1 (nl) 1997-05-01
GB9026776D0 (en) 1991-01-30
FI100883B (fi) 1998-03-13
DE69019481D1 (de) 1995-06-22
CZ280558B6 (cs) 1996-02-14
HUT56073A (en) 1991-07-29
SK280249B6 (sk) 1999-10-08
PT96145A (pt) 1991-09-30
FI973895L (fi) 1997-10-06
DK0432695T3 (da) 1995-09-11
JP2807093B2 (ja) 1998-09-30
HRP930341A2 (en) 1994-10-31
AU634319B2 (en) 1993-02-18
HU211342A9 (en) 1995-11-28
CN1034805C (zh) 1997-05-07
NO905322D0 (no) 1990-12-10
MTP1075B (en) 1991-07-31
LV5738A4 (lv) 1996-08-20
IE67523B1 (en) 1996-04-03
ATE122661T1 (de) 1995-06-15
CN1052482A (zh) 1991-06-26
OA09334A (fr) 1992-09-15
FI973895A7 (fi) 1997-10-06
EG19722A (en) 1996-01-31
KR910011894A (ko) 1991-08-07
FI905983A0 (fi) 1990-12-04
LU90014I2 (fr) 1997-01-31
HU908076D0 (en) 1991-06-28
SI9012315B (sl) 1998-06-30
DZ1467A1 (fr) 2004-09-13
CN1138983A (zh) 1997-01-01
RO107942B1 (ro) 1994-01-31
CA2030433A1 (en) 1991-06-12
NO905322L (no) 1991-06-12
IL96550A (en) 1995-03-15
LTIP862A (en) 1995-03-27
CA2030433C (en) 1997-10-21
EP0432695A3 (en) 1991-12-18
RU2071470C1 (ru) 1997-01-10
ES2072959T3 (es) 1995-08-01
EP0432695B1 (en) 1995-05-17
HRP930341B1 (en) 1998-12-31
BG51452A3 (bg) 1993-05-14
ID1018B (id) 1996-10-18
LV5738B4 (lv) 1996-12-20
MW8890A1 (en) 1991-03-13
GB2239016A (en) 1991-06-19
PL288201A1 (en) 1991-09-09
MX173630B (es) 1994-03-18
HK129093A (en) 1993-12-03
HU207298B (en) 1993-03-29
MA22014A1 (fr) 1991-07-01
GB8927913D0 (en) 1990-02-14
IE904453A1 (en) 1991-06-19
LT3682B (en) 1996-01-25
IL96550A0 (en) 1991-09-16
JPH03255076A (ja) 1991-11-13
IN172553B (enExample) 1993-09-25

Similar Documents

Publication Publication Date Title
KR970005912B1 (en) Amino acids derivatives
PL310895A1 (en) Hiv protease inhibitors in aids treating pharmaceutic compositions
MY111630A (en) Amino acid derivatives.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19901207

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930318

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19901207

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19961121

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970321

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970630

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19970905

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19970905

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000411

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010829

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20020822

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20030825

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20040719

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20050722

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20060714

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20070718

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20080711

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20090716

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20100827

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20100827

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term